Certara UK LIMITED
Acero, England Doing business as Certara Certara UK LIMITED Part of Certara USA Inc.
- UEI
- WWBMG5E7KT69
- CAGE
- U03U4
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Certara USA Inc.
Parent
HWLYE4KDVHB6
- Certara UK LIMITED WWBMG5E7KT69
-
Certara USA Inc.
Parent
HWLYE4KDVHB6
- SAM.gov registration date
- Physical address
- 1 Concourse Way, Sheffield City Centre, Acero, Sheffield S1 2BJ, UK
- Website
- certara.com
- Founded
- 2008
- Employees
- 1K-5K
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| BAA FY26C1CP53: advancing integration of in vitro topical product characterization and skin permeation data | Food and Drug Administration | $352,968 | |
| Software license renewal for simcyp license | Office of Research and Development | $12,390 | |
| Certara simcyp software licenses | Assistant Secretary for Financial Resources | $636,459 | |
| Formulation toolbox for topically applied drugs to account for physical parameters, dynamic metamorphosis and… | FDA Office of Acquisition and Grant Services | $1,499,750 | |
| A state-of-the-art virtual bioequivalence platform and case studies on complex formulations, systemic and local… | FDA Office of Acquisition and Grant Services | $1,249,614 |
About Certara UK LIMITED
Certara UK LIMITED, doing business as Certara, is a for-profit limited liability company registered to receive awards from the U.S. federal government since August 27, 2008. The company specializes in providing advanced modeling and simulation software for drug development and regulatory decision-making. Certara's primary offering to federal agencies is its SIMCYP physiologically-based pharmacokinetic (PBPK) modeling software, which is used to simulate drug absorption, distribution, metabolism, and excretion processes in virtual patient populations. This software is crucial for optimizing drug development processes and facilitating regulatory reviews of new drug applications.
Through federal contract awards, Certara has consistently provided software licenses and maintenance support for its SIMCYP software to key government agencies. The primary recipients of these services have been the Environmental Protection Agency's Office of Research and Development and the Department of Health and Human Services' Food and Drug Administration (FDA). The FDA, particularly its Office of Clinical Pharmacology, utilizes SIMCYP for reviewing investigational new drugs, new drug applications, biologics license applications, and abbreviated new drug applications. Contract values have ranged from small purchases of around $10,000 to larger multi-year agreements exceeding $800,000. These contracts are typically structured as firm-fixed-price purchase orders and are not set aside for specific business categories, indicating Certara's unique position in providing specialized PBPK modeling capabilities to federal agencies.
Certara has also received significant federal grant funding to enhance and expand its PBPK modeling capabilities. Notable among these is a $749,988 cooperative agreement from the FDA's Research program (CFDA 93.103) aimed at improving the SIMCYP PBPK model's ability to account for dynamic changes in topical drug formulations and their impact on drug absorption and bioavailability. Another substantial grant focuses on developing a state-of-the-art virtual bioequivalence platform for complex formulations, systemic and local concentration-based bioequivalence assessments. These grants, typically structured as cooperative agreements, demonstrate Certara's ongoing collaboration with federal agencies to advance drug development methodologies, reduce the need for clinical trials, and improve drug efficacy and safety assessments. The company's grant-funded work particularly emphasizes enhancing modeling capabilities for topical drug products and virtual bioequivalence assessments, which are critical for accelerating generic drug development and regulatory approvals.
Quick answers
What is Certara UK LIMITED's UEI?
Certara UK LIMITED's Unique Entity ID (UEI) in SAM.gov is WWBMG5E7KT69.
What is Certara UK LIMITED's CAGE code?
Certara UK LIMITED's CAGE code is U03U4.
What is Certara UK LIMITED's primary NAICS code?
Certara UK LIMITED's primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Certara UK LIMITED located?
Certara UK LIMITED's physical address in SAM.gov is 1 Concourse Way, Sheffield City Centre, Acero, Sheffield S1 2BJ, UK.
Is Certara UK LIMITED registered in SAM.gov?
Yes. Certara UK LIMITED's SAM.gov registration is active through October 31, 2026.
Who is Certara UK LIMITED's parent company?
Certara UK LIMITED is part of Certara USA Inc.
What is Certara UK LIMITED's most recent federal award?
Certara UK LIMITED's most recent federal contract award is BAA FY26C1CP53: advancing integration of in vitro topical product characterization and skin permeation data (75F40126C00071), from Food and Drug Administration, on September 30, 2026.
On GovTribe
See Certara UK LIMITED's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors